Azopt (brinzolamide) NDC 66758-085

NDC codes

FDA NDC Directory

Product NDC (as listed)66758-085Labeler and product segments. Claims need a package NDC.

Product NDC at billing width66758-0085Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
66758-085-70	66758008570	1 BOTTLE in 1 CARTON (66758-085-70) / 10 mL in 1 BOTTLEMarketed from Oct 25, 2024
66758-085-85	66758008585	1 BOTTLE in 1 CARTON (66758-085-85) / 15 mL in 1 BOTTLEMarketed from Nov 15, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Azopt
Generic name (nonproprietary): brinzolamide
Active ingredients: Brinzolamide — 10 mg/mL
Dosage form: Suspension/ drops
Route: Ophthalmic
Labeler: Sandoz Inc
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 020816
Marketing start: Apr 30, 1998
Listing expires: Dec 31, 2026
Other FDA classes: Carbonic Anhydrase Inhibitors (Mechanism)
Identifiers: Product ID 66758-085_0afb6589-51ba-432c-aed1-20a12d5d3455SPL ID 0afb6589-51ba-432c-aed1-20a12d5d3455SPL set ID 0afb6589-51ba-432c-aed1-20a12d5d3455RxCUI 213272, 308805UNII 9451Z89515
Pharmacologic class: Carbonic Anhydrase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Ophthalmic products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N466758008570 followed by a unit qualifier and the quantity

Package 66758-0085-70. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 24, 2023.

Indications (excerpt from the label)

AZOPT is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. AZOPT is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 020816

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 020816
Product	Strength	Form · route	Labeler	Product NDC
Brinzolamide	Brinzolamide 10 mg/mL	Suspension/ dropsOphthalmic	Sandoz Inc	0781-6014